MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, AURX had $198,443 increase in cash & cash equivalents over the period. -$706,516 in free cash flow.

Cash Flow Overview

Change in Cash
$198,443
Free Cash flow
-$706,516

Unit: Dollar
Cash Flow
2025-09-30
2025-06-30
Net loss
-537,919 -1,395,817
Depreciation expense
23,148 38,403
Stock-based compensation
19,915 42,544
Provision for credit losses
28,876 12,525
Provision for inventory obsolescence
0 9,119
Vendor expense settled in shares of common stock
18,000 15,000
Amortization of operating lease right of use assets
18,073 34,905
Accounts receivable, net
360,688 84,760
Inventory, net
35,811 24,493
Prepaid expenses and other current assets
43,307 -108,515
Accounts payable
178,775 93,694
Accrued expenses
76,338 22,154
Deferred revenue
-75,000 1,425,000
Operating lease liabilities
-16,916 -32,598
Net cash used in operating activities
-706,516 264,191
Purchases of property and equipment
0 231,551
Net cash used in investing activities
0 -231,551
Net proceeds from issuance of common stock
791,418 0
Net proceeds from option exercises
113,541 -
Net proceeds from warrant exercise
0 0
Net cash provided by financing activities
904,959 0
Net increase (decrease) in cash
198,443 32,640
Cash and cash equivalents at beginning of period
283,714 -
Cash and cash equivalents at end of period
514,797 -
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Nuo Therapeutics, Inc. (AURX)

Nuo Therapeutics, Inc. (AURX)